Literature DB >> 7478565

Abrogation of p53-induced cell cycle arrest by c-Myc: evidence for an inhibitor of p21WAF1/CIP1/SDI1.

H Hermeking1, J O Funk, M Reichert, J W Ellwart, D Eick.   

Abstract

The tumor-suppressor p53 inhibits cell cycle progression by direct transactivation of the p21WAF1/CIP1/SDI1 gene, which encodes a universal inhibitor of cyclin dependent kinases (cdk). The proto-oncogene product c-Myc induces cell cycle progression and, in the absence of survival factors, apoptosis. However, a direct link between the cell cycle machinery and c-Myc has not yet been established. We show that c-Myc has not yet been established. We show that c-Myc abrogates a p53-induced G1-arrest without elevating the expression of cdks or cyclins involved in the G1/S-transition. Instead, the results suggest that c-Myc interferes with the inhibitory action of p21 on cdk/cyclin-complexes by inducing a heat-labile inhibitor of p21. The inactivation of p21 and related cdk-inhibitors may explain several of the oncogenic actions of c-Myc, including the induction of proliferation, immortalisation and the inhibition of differentiation. Modulation of cdk activity by the induction of an inhibitor of cdk-inhibitors represents a novel mechanism of cell cycle regulation in mammalian cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7478565

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  25 in total

1.  Transient excess of MYC activity can elicit genomic instability and tumorigenesis.

Authors:  D W Felsher; J M Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

2.  Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells.

Authors:  M Kortylewski; P C Heinrich; M E Kauffmann; M Böhm; A MacKiewicz; I Behrmann
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

3.  Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression.

Authors:  Asa Karlsson; Debabrita Deb-Basu; Athena Cherry; Stephanie Turner; James Ford; Dean W Felsher
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-08       Impact factor: 11.205

4.  Cyclin E and c-Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins.

Authors:  K Alevizopoulos; J Vlach; S Hennecke; B Amati
Journal:  EMBO J       Date:  1997-09-01       Impact factor: 11.598

5.  AP4 encodes a c-MYC-inducible repressor of p21.

Authors:  Peter Jung; Antje Menssen; Doris Mayr; Heiko Hermeking
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-25       Impact factor: 11.205

6.  c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry.

Authors:  O W Prall; E M Rogan; E A Musgrove; C K Watts; R L Sutherland
Journal:  Mol Cell Biol       Date:  1998-08       Impact factor: 4.272

7.  p21CIP1 and Cdc25A: competition between an inhibitor and an activator of cyclin-dependent kinases.

Authors:  P Saha; Q Eichbaum; E D Silberman; B J Mayer; A Dutta
Journal:  Mol Cell Biol       Date:  1997-08       Impact factor: 4.272

8.  Identification of CDK4 as a target of c-MYC.

Authors:  H Hermeking; C Rago; M Schuhmacher; Q Li; J F Barrett; A J Obaya; B C O'Connell; M K Mateyak; W Tam; F Kohlhuber; C V Dang; J M Sedivy; D Eick; B Vogelstein; K W Kinzler
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-29       Impact factor: 11.205

9.  p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest.

Authors:  Jenny S L Ho; Weili Ma; Daniel Y L Mao; Samuel Benchimol
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

10.  Myc down-regulation affects cyclin D1/cdk4 activity and induces apoptosis via Smac/Diablo pathway in an astrocytoma cell line.

Authors:  D Amendola; M De Salvo; R Marchese; C Verga Falzacappa; A Stigliano; E Carico; E Brunetti; M Moscarini; B Bucci
Journal:  Cell Prolif       Date:  2009-02       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.